Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.51 |
| ▸ | DRD3 | P35462 | 6/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25232145 | 0.85 | ADRB1 (0.45) | DRD2DRD3ADRB1METKCNH2 | |
| SCHEMBL12968839 | 0.84 | ADRB1 (0.61) | ADRB1METKCNH2ALDH1A1KMT2A | |
| SCHEMBL30890970 | 0.83 | ADRB1 (0.73) | DRD2DRD3ADRB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4075268 | 0.83 | ADRB1 (0.73) | DRD2DRD3ADRB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3530448 | 0.82 | ADRB1 (0.49) | DRD2DRD3ADRB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7058593 | 0.79 | DRD2 (0.59) | DRD2DRD3 | |
| SCHEMBL18255830 | 0.78 | ADRB1 (0.50) | ADRB1METKCNH2ALDH1A1SMN1; SMN2 | |
| SCHEMBL428031 | 0.78 | ADRB1 (0.50) | ADRB1METKCNH2ALDH1A1 | |
| SCHEMBL15077174 | 0.78 | ADRB1 (0.54) | ADRB1METKCNH2ALDH1A1 | |
| SCHEMBL273503 | 0.76 | ADRA2C (0.53) | ADRB1METKCNH2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9493455-B2 | Azaindole derivatives as inhibitors of protein kinases | ORIBASE PHARMA (FR) | 2016-11-15 | — | — | US | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| EP-2938613-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | OriBase Pharma (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2938612-A1 | PROTEIN KINASE INHIBITORS | OriBase Pharma (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2938614-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | OriBase Pharma (FR) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014102378-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014102377-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014102376-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2014-07-03 | — | — | WO | disclosed |
| US-7655669-B2 | Pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| EP-1546127-B1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| EP-1546127-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029038-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K3, MAP3K20 | DRD2 3170/4885DRD3 2941/4885ADRB1 1990/4885 |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | MAP2K2, MAP2K5, MAP2K3 | DRD2 2787/4885DRD3 2784/4885ADRB1 1923/4885 |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | DRD2 4828/4885DRD3 4769/4885ADRB1 2194/4885 |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | TYMP, NME2, DPYD | DRD2 4505/4885DRD3 4698/4885ADRB1 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.